AstraZeneca Q2 profit beats estimates as cancer drug sales drive growth

businessinsider

Jul 27, 2026 at 03:14 AM

AstraZeneca reported Q2 earnings beating estimates, with core EPS rising to $2.63 and revenue reaching $15.38B, driven by strong sales of cancer drugs Enhertu, Imfinzi, and Tagrisso. Despite a disappointing trial for heart disease drug Wainua causing an 8% YTD stock drop, CEO Pascal Soriot reaffirmed FY2026 guidance, expressing confidence in long-term growth and the company's robust pipeline.

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.